The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy

Osteoporosis International

Volumn 23, Issue 11, 2012, Pages 2703-2711

  Sbrocchi, A M ^a   Rauch, F ^b   Jacob, P ^a   McCormick, A ^a   McMillan, H J ^a   Matzinger, M A ^a   Ward, L M ^a  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b SHRINERS HOSPITAL FOR CHILDREN   (Canada)

Author keywords

Bisphosphonates; Bone histomorphometry; Bone mineral density; Clinical pediatrics; Corticosteroid osteoporosis; Vertebral fractures

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADOLESCENT; ARTICLE; BACKACHE; BONE DENSITOMETRY; BONE DENSITY; CHILD; CLINICAL ARTICLE; DISEASE SEVERITY; DUCHENNE MUSCULAR DYSTROPHY; FEVER; HEART FAILURE; HUMAN; HYPOCALCEMIA; LIMB FRACTURE; LUMBAR SPINE; MALAISE; MALE; MORPHOMETRICS; NAUSEA AND VOMITING; OBSERVATIONAL STUDY; OSTEOPOROSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SPINE FRACTURE; VERTEBRA BODY; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; BACK PAIN; BIOPSY; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CHILD; DIPHOSPHONATES; DRUG EVALUATION; GLUCOCORTICOIDS; HUMANS; ILIUM; INFUSIONS, INTRAVENOUS; MALE; MUSCULAR DYSTROPHY, DUCHENNE; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RETROSPECTIVE STUDIES; SPINAL FRACTURES; TREATMENT OUTCOME;

EID: 84868208578     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-012-1911-3     Document Type: Article

References (48)

1. Soderpalm AC, Magnusson P, Ahlander AC, Karlsson J, Kroksmark AK, Tulinius M, Swolin-Eide D (2007) Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy. Neuromuscul Disord 17:919-928
2. Yilmaz O, Karaduman A, Topaloglu H (2004) Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis. Eur J Neurol 11:541-544
3. Biggar WD, Gingras M, Fehlings DL, Harris VA, Steele CA (2001) Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr 138:45-50
4. Bianchi ML, Mazzanti A, Galbiati E, Saraifoger S, Dubini A, Cornelio F, Morandi L (2003) Bone mineral density and bone metabolism in Duchenne muscular dystrophy. Osteoporos Int 14:761-767
5. Larson CM, Henderson RC (2000) Bone mineral density and fractures in boys with Duchenne muscular dystrophy. J Pediatr Orthop 20:71-74
6. Bothwell JE, Gordon KE, Dooley JM, MacSween J, Cummings EA, Salisbury S (2003) Vertebral fractures in boys with Duchenne muscular dystrophy. Clin Pediatr (Phila) 42:353-356
7. King WM, Ruttencutter R, Nagaraja HN, Matkovic V, Landoll J, Hoyle C, Mendell JR, Kissel JT (2007) Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 68:1607-1613
8. Houde S, Filiatrault M, Fournier A, Dube J, D'Arcy S, Berube D, Brousseau Y, Lapierre G, Vanasse M (2008) Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatr Neurol 38:200-206
9. Talim B, Malaguti C, Gnudi S, Politano L, Merlini L (2002) Vertebral compression in Duchenne muscular dystrophy following deflazacort. Neuromuscul Disord: NMD 12:294-295
10. Hawker GA, Ridout R, Harris VA, Chase CC, Fielding LJ, Biggar WD (2005) Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy. Arch Phys Med Rehabil 86:284-288
11. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947-952
12. Sumnik Z, Land C, Rieger-Wettengl G, Korber F, Stabrey A, Schoenau E (2004) Effect of pamidronate treatment on vertebral deformity in children with primary osteoporosis. A pilot study using radiographic morphometry. Horm Res 61:137-142
13. Brumsen C, Hamdy NA, Papapoulos SE (1997) Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Med (Baltimore) 76:266-283
14. Gafni RI, McCarthy EF, Hatcher T, Meyers JL, Inoue N, Reddy C, Weise M, Barnes KM, Abad V, Baron J (2002) Recovery from osteoporosis through skeletal growth: early bone mass acquisition has little effect on adult bone density. FASEB J 16:736-738
15. Rauch F, Munns CF, Land C, Cheung M, Glorieux FH (2009) Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Bone Miner Res 24:1282-1289
16. Bishop N, Harrison R, Ahmed F et al (2010) A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. J Bone Miner Res 25:32-40
17. Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-1148
18. Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R, Grummer-Strawn LM, Curtin LR, Roche AF, Johnson CL (2002) Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics 109:45-60
19. Marshall WA, Tanner JM (1969) Variations in pattern of pubertal changes in girls. Arch Dis Child 44:291-303
20. Marshall WA, Tanner JM (1970) Variations in the pattern of pubertal changes in boys. Arch Dis Child 45:13-23
21. van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777-787
22. Institute of Medicine (1997) Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, fluoride. National Academy, Washington
23. Rauchenzauner M, Schmid A, Heinz-Erian P, Kapelari K, Falkensammer G, Griesmacher A, Finkenstedt G, Hogler W (2007) Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years. J Clin Endocrinol Metab 92:443-449
24. Greulich WW, Pyle SI (1959) Radiographic atlas of skeletal development of the hand and wrist, 2nd edn. Stanford University Press, Stanford
25. Spencer RP, Sagel SS, Garn SM (1968) Age changes in five parameters of metacarpal growth. Invest Radiol 3:27-34
26. Garn SM, Mayor GH, Shaw HA (1976) Paradoxical bilateral asymmetry in bone size and bone mass in the hand. Am J Phys Anthropol 45:209-210
27. Kroger H, Vainio P, Nieminen J, Kotaniemi A (1995) Comparison of different models for interpreting bone mineral density measurements using DXA and MRI technology. Bone 17:157-159
28. van der Sluis IM, de Ridder MA, Boot AM, Krenning EP, de Muinck Keizer-Schrama SM (2002) Reference data for bone density and body composition measured with dual energy x ray absorptiometry in white children and young adults. Arch Dis Child 87:341-347, discussion 341-347
29. Armbrecht G, Blenk T, Chesnut CH 3rd, Gardner JC, von Ingersleben G, Mahoney P, Felsenberg D (2008) Vertebral fracture diagnosis in the multinational BONE study of oral ibandronate: quality management in radiology. J Clin Densitom 11:221-231
30. Ravaud P, Reny JL, Giraudeau B, Porcher R, Dougados M, Roux C (1999) Individual smallest detectable difference in bone mineral density measurements. J Bone Miner Res: Off J Am Soc Bone Miner Res 14:1449-1456
31. Bland JM, Altman DG (1999) Measuring agreement in method comparison studies. Stat Methods: Med Res 8:135-160
32. Glorieux FH, Travers R, Taylor A, Bowen JR, Rauch F, Norman M, Parfitt AM (2000) Normative data for iliac bone histomorphometry in growing children. Bone 26:103-109
33. Glorieux FH, Rauch F (2006) Medical therapy of children with fibrous dysplasia. J Bone Miner Res 21(Suppl 2):P110-P113
34. Rauch F, Travers R, Plotkin H, Glorieux FH (2002) The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110:1293-1299
35. Munns CF, Rauch F, Travers R, Glorieux FH (2005) Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. J Bone Miner Res 20:1235-1243
36. Baim S, Leonard MB, Bianchi ML, Hans DB, Kalkwarf HJ, Langman CB, Rauch F (2008) Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Pediatric Position Development Conference. J Clin Densitom 11:6-21
37. Gaca AM, Barnhart HX, Bisset GS 3rd (2010) Evaluation of wedging of lower thoracic and upper lumbar vertebral bodies in the pediatric population. AJR Am J Roentgenol 194:516-520
38. Weinstein RS, Jilka RL, Almeida M, Roberson PK, Manolagas SC (2010) Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice. Endocrinology 151:2641-2649
39. Plotkin H, Coughlin S, Kreikemeier R, Heldt K, Bruzoni M, Lerner G (2006) Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study. Dev Med Child Neurol 48:709-712
40. Howe W, Davis E, Valentine J (2010) Pamidronate improves pain, wellbeing, fracture rate and bone density in 14 children and adolescents with chronic neurological conditions. Dev Neurorehabil 13:31-36
41. Glorieux FH, Bishop N, Bober M et al (2008) Intravenous zoledronic acid (zol) compared to IV pamidronate (PAM) in children with severe osteogenesis imperfecta (OI). Calcif Tissue Int 82(Suppl 1):S85
42. Halton J, Gaboury I, Grant R et al (2009) Advanced vertebral fracture among newly diagnosed children with acute lymphoblastic leukemia: results of the Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) research program. J Bone Miner Res 24:1326-1334
43. Huber A, Gaboury I, Cabral DA et al (2010) Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders. Arth Care Res 62:516-526
44. Rodd C, Lang B, Ramsay T et al (2012) Incident vertebral fractures among children with rheumatic disorders 12 months post-glucocorticoid initiation: a national observational study. Arthritis Care Res 64(1):122-131
45. Thearle M, Horlick M, Bilezikian JP, Levy J, Gertner JM, Levine LS, Harbison M, Berdon W, Oberfield SE (2000) Osteoporosis: an unusual presentation of childhood Crohn's disease. J Clin Endocrinol Metab 85:2122-2126
46. Pandya NA, Meller ST, MacVicar D, Atra AA, Pinkerton CR (2001) Vertebral compression fractures in acute lymphoblastic leukaemia and remodelling after treatment. Arch Dis Child 85:492-493
47. Simm PJ, Johannesen J, Briody J, McQuade M, Hsu B, Bridge C, Little DG, Cowell CT, Munns CF (2011) Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis. Bone 49:939-943
48. Gordon KE, Dooley JM, Sheppard KM, MacSween J, Esser MJ (2011) Impact of bisphosphonates on survival for patients with Duchenne muscular dystrophy. Pediatrics 127:e353-e358